Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-dose NT201 botulinum toxin satisfaction study
NL-OMON59533Phase 3Completed
- Sponsor
- Falck
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of botulinum toxin type A in facial rhytids, rhytides and fine lines, sponsored by Falck. Started Jan 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
facial rhytidsrhytidesfine lines
Beyond the preview
Go deeper on NL-OMON59533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59533.